Lucira Health announced it filed for Chapter 11 bankruptcy last week just as the diagnostics company received Emergency Use Authorization from the FDA for an at-home combination COVID-19 and flu test.
In the company's bankruptcy filing, it lists about $146 million in assets and liabilities of around $85 million. Lucira plans to use approximately $4.5 million cash on hand to fund operations as it...
Less than a year after it went public, diagnostics company Cue Health has laid off 170 manufacturing workers.
First reported by STAT, Cue said the layoffs reflected larger economic conditions, as well as the federal government's recent move to divert funding from COVID-19 testing to secure vaccines and treatments.
The diagnostics company is best known for its at-home molecular COVID-19 test,...
New Zealand-based Rfider links COVID-19 test with digital health pass for travel
New Zealand software firm Rfider has enabled a COVID-19 test in Singapore to connect with a digital health pass for international travel.
In a statement, the company said it has been chosen by Invitrocue, a Singapore-based bioanalytic solutions provider, to empower its saliva-based antigen and PCR-based COVID-19...
Regulatory body approves POC use of Cue Health's COVID-19 test in India
Cue Health, a California-based health tech company, has recently got regulatory approval from the Central Drugs Standard Control Organisation for its COVID-19 test for professional point-of-care use in India.
The company claims its molecular-based diagnostic test provides "highly accurate, lab-quality results" that are sent...
AI diagnostics startup MediCircle Health has recently introduced in India a rapid spectrometry-based test that employs machine learning and artificial intelligence to detect COVID-19.
WHAT IT DOES
Spectral Instant Test (SpectraLIT) is a point-of-care diagnostic platform that performs spectral analysis to accurately and instantly determine if a spectral pattern of a virus from a nasal or mouthwash...
Researchers at the University of Pennsylvania School of Medicine have developed a diagnostic test for COVID-19 made of scalable materials that can deliver results within minutes at a fraction of the cost of other tests.
Called RAPID 1.0 (Real-time Accurate Portable Impedimetric Detection prototype 1.0), the test was developed as an alternative to RT-PCR tests, which require trained laboratory...
This week, the Food and Drug Administration shared that it will allow marketing for some COVID-19 screening tests before their effectiveness is studied in asymptomatic individuals.
Test developers seeking this over-the-counter authorization can apply using a template provided by the FDA to share data on who the test is intended for and how well the test works, and provide instructions for its use...
The Biden administration has cut a deal with Australian digital diagnostics company Ellume to increase the availability of its at-home rapid response COVID-19 test kit in the U.S.
The Department of Defense, with the Department of Health and Human Services, will pay $231.8 million for Ellume to deliver 8.5 million tests across the U.S. in accordance with the National Strategy for the COVID-19...
Yesterday afternoon, the U.S. FDA issued an Emergency Use Authorization (EUA) to a COVID-19 molecular diagnostic test that provides individuals with a result within 30 minutes, in the comfort of their home.
As opposed to currently available at-home testing products, which have patients self-collect a nasal swab sample and ship it for processing in a lab, the Lucira COVID-19 All-in-One Test Kit...
Hogwash, or a brain activity breakthrough? Friday evening came with a long-awaited look at the work of Neuralink, Elon Musk's ambitious brain-computer interface implant startup. In the streamed progress update, Musk ran down a PowerPoint overview of the technology's capabilities, which he likened to "a Fitbit in your skull." The coin-shaped implant will read and wirelessly transmit brain signals...
